Miruvor
Sign up
The short answer

What studies of Anakinra (Kineret) found

5papers on Anakinra (Kineret)
25people in 1 study testing Anakinra (Kineret) alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: D Little or no difference

Based on the strongest evidence, the placebo trial (low certainty): 4 findings, all D.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with Anakinra (Kineret) for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 5 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Anakinra (Kineret) · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Fatigue1 study · 25 people received Anakinra (Kineret) Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 50 people found no clear difference; a small benefit can't be ruled out.

The placebo trial50 randomised · 4 weeks · 100 mg, daily

No clear difference in fatigue.

Anakinra (Kineret) may make little or no difference to fatigue in ME/CFS. Little or no difference · low certainty D

  • One trial of 50 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. (2017)

    People in the study
    50 randomised
    Dose
    100 mg, daily
    Outcome
    CIS-fatigue score (after treatment) Checklist Individual Strength
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Low mood or anxiety1 study · 25 people received Anakinra (Kineret) Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 50 people found no clear difference; a small benefit can't be ruled out.

The placebo trial50 randomised · 4 weeks · 100 mg, daily

No clear difference in low mood or anxiety.

Anakinra (Kineret) may make little or no difference to low mood or anxiety in ME/CFS. Little or no difference · low certainty D

  • One trial of 50 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. (2017)

    People in the study
    50 randomised
    Dose
    100 mg, daily
    Outcome
    SCL-90 score Symptom Checklist-90
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Pain1 study · 25 people received Anakinra (Kineret) Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 50 people found no clear difference; a small benefit can't be ruled out.

The placebo trial50 randomised · 4 weeks · 100 mg, daily

No clear difference in pain.

Anakinra (Kineret) may make little or no difference to pain in ME/CFS. Little or no difference · low certainty D

  • One trial of 50 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. (2017)

    People in the study
    50 randomised
    Dose
    100 mg, daily
    Outcome
    Maximum VAS pain score visual analogue scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Daily life and health overall

Daily functioning1 study · 25 people received Anakinra (Kineret) Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 50 people found no clear difference; a small benefit can't be ruled out.

The placebo trial50 randomised · 4 weeks · 100 mg, daily

No clear difference in daily functioning.

Anakinra (Kineret) may make little or no difference to daily functioning in ME/CFS. Little or no difference · low certainty D

  • One trial of 50 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. (2017)

    People in the study
    50 randomised
    Dose
    100 mg, daily
    Outcome
    SF-36 score Physical functioning Short Form-36 Health Survey
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Side effects

Stopping because of side effects1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    100 mg at the start

  2. 2Top dose

    Most often 100 mg (2 of 2 studies)

Doses across 2 studies

100 to 100 mg.

Each study’s dose, as printed

All papers

  1. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial.2017 · placebo trial · 50 randomised
    Summary

    This randomized, placebo-controlled trial asked whether blocking interleukin-1 with anakinra reduces fatigue severity in women with chronic fatigue syndrome (CFS). Fifty women aged 18 to 59 years with CFS and severe fatigue leading to functional impairment were randomly assigned to daily subcutaneous anakinra 100 mg (n = 25) or placebo (n = 25) for 4 weeks, then followed for 20 more weeks. The primary outcome was fatigue severity on the Checklist Individual Strength CIS-fatigue subscale at 4 weeks; secondary outcomes included impairment, physical and social functioning, psychological distress, and pain at 4 and 24 weeks. At 4 weeks, the mean between-group difference in CIS-fatigue score was 1.5 points (95% CI, -4.1 to 7.2 points); the paper reports no clinically important or statistically significant differences at 4 weeks or end of follow-up, and no statistically significant between-group differences for secondary outcomes. A fatigue level within the range reported by healthy persons was reached by 2 of 25 (8%) anakinra recipients and 5 of 25 (20%) placebo recipients. One patient in the anakinra group discontinued treatment because of an adverse event (local skin infection). Injection site reactions occurred in 17 of 25 (68%) anakinra recipients vs 1 of 25 (4%) placebo recipients; at least one adverse event occurred in 24 of 25 (96%) vs 14 of 25 (56%). No serious adverse events occurred. The authors state limitations including small sample size and wide variability in symptom duration, and that inclusion was not limited to patients with postinfectious symptoms.

  2. Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment.2017 · placebo trial · 50 randomised
    Summary

    This paper looked at blood immune markers (cytokines) in women with ME/CFS taking part in a trial of anakinra, a drug that blocks interleukin-1. Fifty women who met the CDC criteria, seen at an expert fatigue centre in Nijmegen, the Netherlands, were randomly given daily injections under the skin of anakinra (100 mg a day) or a placebo for four weeks; 25 got anakinra. Patients also brought a healthy neighbour of similar age, whose blood was taken once for comparison. The trial's main results on symptoms were reported in another paper; this paper reports only blood markers, so it gives no symptom outcome for anakinra. The authors report that, after correction for multiple testing, anakinra did not change the circulating cytokines apart from raising the level of the drug's own marker, IL-1Ra. One woman in the anakinra group stopped treatment after 2 weeks following an adverse event, which the paper does not describe, and was left out of the analysis. Patients and healthy controls differed in a few markers. The authors note that the number of patients was small compared with the number of markers measured.

  3. Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID Syndrome2022 · compared with another group
    Summary

    Why: The study examined whether progression of severe pneumonia into post-acute COVID-19 syndrome (PACS) is associated with long-term immune dysregulation. Who: Patients with known history of COVID-19 pneumonia during two different time periods and matched comparators were divided into a discovery cohort (n=46, September-October 2020) and a validation cohort (n=484, June-August 2021). What was given: The abstract reports anti-IL-1 treatment with anakinra during the acute phase of disease; the text does not report dose, route, or duration. Compared with: The cohorts included matched comparators; the anakinra statement in the abstract does not name a comparator arm. Measured: Peripheral blood mononuclear cells were stimulated for cytokine production; patient-reported questionnaires and lung function tests were analyzed. Found: Increased production of interleukin (IL)-1β (p<0.001) and IL-6 (p<0.001) was found in post-COVID-19 patients from both study periods. Anti-inflammatory Th2 responses and Th17 responses were attenuated compared to controls. PACS was present in 22%: fatigue was associated with predominance of Th2 responses; abnormal LFTs with overproduction of IL-1β and IL-6. Epigenetic markers of chromatin accessibility such as H3K27Ac were associated with these changes. The abstract states anti-IL-1 treatment with anakinra during the acute phase reduced the chance of developing PACS by 40%. Side effects and withdrawals: not reported. Limits: the text does not state limitations.

  4. Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient.2025 · case report · 3 in the study
    Summary

    This paper reports case reports of 3 patients with long COVID and predominant neuropsychiatric symptoms, 2 with autism spectrum disorder (ASD) and one without ASD, seen in the Pediatric Allergy/Immunology Clinic and the authors' clinic. Upadacitinib, a JAK1 inhibitor, was added to treatment that included colchicine; doses recorded were 15 mg once daily, 30 mg once daily, and 15 mg/day increased to 30 mg/day. Treatment duration was not reported. There was no comparison group; changes were assessed before and after upadacitinib. The Aberrant Behavior Check list (ABC) was used in all 3 cases. The authors report noticeable improvement in all ABC subscale scores in the 3 cases; improvement in irritability, lethargy, and hyperactivity within 1–2 weeks in all three cases; and improvement in Case 3 stereotypy. Case 2 appeared to regain some cognitive functioning six months after starting upadacitinib, and speech improved. Case 3 tic symptoms gradually subsided over 4–5 months. Monocyte cytokine data were available for cases 1 and 3. One tonic-clonic seizure occurred in Case 1 when the lamotrigine dose was lowered. The authors state difficulty diagnosing long COVID in ASD cases.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime